Lymphoma Clinical Trials

Norton Cancer Institute is at the forefront of cancer treatment research. As principal investigators on numerous trials, our specialist physicians have access to innovative treatments.

Learn more about participating in a clinical trial at Norton Healthcare.

Active lymphoma trials at Norton Cancer Institute include:

B-Cell Non-Hodgkin Lymphoma (NHL)

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (017006)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Classical Hodgkin Lymphoma (cHL)

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Diffuse Large B-cell Lymphoma (DLBCL)

A Randomized Phase 3 Study to Evaluate the efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1. (ENGINE Study)

Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

Diffuse Large B-cell Lymphoma (DLBCL)

Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory DLBCL

Follicular Lymphoma

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

Follicular Lymphoma

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma

Hodgkin Lymphoma

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology

Lymphoma

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Lymphoma

A PHASE 1/2A OPEN-LABEL, MULTI-DOSE, MULTI-CENTER ESCALATION AND EXPLORATORY STUDY OF CERDULATINIB(PRT062070) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR B-CELL or T-CELL NON-HODGKIN LYMPHOMA (NHL)

Lymphoma

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

Lymphoma

Extended treatment protocol for subjects continuing to benefit from Ibrutinib after completion of Ibrutinib (PCI-32965) clinical trials.

Mantle Cell Lymphoma (MCL)

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Non-Hodgkin’s Lymphoma

Open-label, 2-arm, randomized, controlled Phase III trial of intravenous PI3K inhibitor copanlisib as monotherapy and in combination with rituximab, compared to rituximab monotherapy, in subjects with indolent B-cell non-Hodgkin lymphoma

Non-Hodgkin’s Lymphoma

A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibodyradionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

Non-Hodgkin’s Lymphoma

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma

Small Cell Lung Cancer (SCLC)

A Phase 1 Dose Escalation and Expanded Cohort Study of PF-06821497 in the treatment of adult patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC), and Follicular Lymphoma (FL)

T-Cell Lymphoma

Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K ?/? dual inhibitor given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory […]

Cancer – 4673

Appointments

Cancer care that isn’t too far from home.

(502) 629-HOPE (4673)


Request an Appointment Online

Clinical trials

Clinical Trials

Learn more about clinical trials at Norton Healthcare
(502) 629-3501

Art therapist’s breast cancer journey fuels passion to help others with the disease

While Leigh Galloway undergoes her last chemotherapy treatment before a double mastectomy, she and Laura Chamberlin are engrossed in a watercolor. Like she does often with Laura, an expressive art therapist with Norton Cancer Institute […]

Read Full Story

Pathology lab provides expertise in cancer and other conditions

Patients don’t see pathologists, but these physicians can make all the difference when it comes to diagnosing and treating cancer and other conditions, said Alvin W. Martin, M.D., medical director for Norton Healthcare’s CPA Lab. [...]

Read Full Story

Bringing new gynecologic cancer treatments and caring for patients like family

After working as an obstetrician/gynecologist for five years, Charles B. Palmer, D.O., was drawn to patients needing complex care. He decided to become a gynecologic oncologist, diagnosing and treating cancers in women’s reproductive organs. “The [...]

Read Full Story

Bike to Beat Cancer raises more than $525,000 for Norton Cancer Institute

Riders, donors and everyone who participated in the 11th annual Bike to Beat Cancer raised more than $525,000 for Norton Cancer Institute. The Saturday, Sept. 14, ride began and ended at Norton Cancer Institute – […]

Read Full Story

An oncologist with a passion for people and leading-edge science

Chandler H. Park, M.D., knew he wanted to travel to get his medical education, but he also knew he’d find his way back home. Dr. Park’s education and clinical experience have taken him to the […]

Read Full Story
Related Stories

Art therapist’s breast cancer journey fuels passion to help others with the disease

While Leigh Galloway undergoes her last chemotherapy treatment before a double mastectomy, she and Laura Chamberlin are engrossed in a watercolor. Like she does often with Laura, an expressive art therapist with Norton Cancer Institute […]

Read Full Story

Pathology lab provides expertise in cancer and other conditions

Patients don’t see pathologists, but these physicians can make all the difference when it comes to diagnosing and treating cancer and other conditions, said Alvin W. Martin, M.D., medical director for Norton Healthcare’s CPA Lab. [...]

Read Full Story

Bringing new gynecologic cancer treatments and caring for patients like family

After working as an obstetrician/gynecologist for five years, Charles B. Palmer, D.O., was drawn to patients needing complex care. He decided to become a gynecologic oncologist, diagnosing and treating cancers in women’s reproductive organs. “The [...]

Read Full Story

Bike to Beat Cancer raises more than $525,000 for Norton Cancer Institute

Riders, donors and everyone who participated in the 11th annual Bike to Beat Cancer raised more than $525,000 for Norton Cancer Institute. The Saturday, Sept. 14, ride began and ended at Norton Cancer Institute – […]

Read Full Story

An oncologist with a passion for people and leading-edge science

Chandler H. Park, M.D., knew he wanted to travel to get his medical education, but he also knew he’d find his way back home. Dr. Park’s education and clinical experience have taken him to the […]

Read Full Story

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.